Odyssean LLC Sells 12,852 Shares of Supernus Pharmaceuticals, Inc. $SUPN

Odyssean LLC reduced its stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 46.6% in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 14,738 shares of the specialty pharmaceutical company’s stock after selling 12,852 shares during the quarter. Odyssean LLC’s holdings in Supernus Pharmaceuticals were worth $685,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in SUPN. Rockefeller Capital Management L.P. grew its holdings in Supernus Pharmaceuticals by 354.8% during the fourth quarter. Rockefeller Capital Management L.P. now owns 846 shares of the specialty pharmaceutical company’s stock valued at $42,000 after purchasing an additional 660 shares during the last quarter. EverSource Wealth Advisors LLC bought a new position in shares of Supernus Pharmaceuticals in the second quarter valued at approximately $51,000. Hantz Financial Services Inc. raised its position in shares of Supernus Pharmaceuticals by 73.3% in the fourth quarter. Hantz Financial Services Inc. now owns 1,083 shares of the specialty pharmaceutical company’s stock valued at $54,000 after purchasing an additional 458 shares during the period. Raymond James Financial Inc. acquired a new stake in shares of Supernus Pharmaceuticals in the second quarter worth $55,000. Finally, Osaic Holdings Inc. boosted its holdings in shares of Supernus Pharmaceuticals by 211.5% during the 2nd quarter. Osaic Holdings Inc. now owns 1,956 shares of the specialty pharmaceutical company’s stock worth $63,000 after buying an additional 1,328 shares during the period.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the stock. Wall Street Zen lowered shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Weiss Ratings reissued a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research report on Wednesday, June 24th. Cantor Fitzgerald upped their price target on shares of Supernus Pharmaceuticals from $63.00 to $67.00 and gave the company an “overweight” rating in a report on Thursday, July 9th. Finally, Zacks Research raised Supernus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $62.83.

Supernus Pharmaceuticals Trading Down 1.0%

Shares of Supernus Pharmaceuticals stock opened at $43.53 on Friday. The company’s fifty day simple moving average is $46.69 and its 200-day simple moving average is $48.41. The company has a market cap of $2.53 billion, a price-to-earnings ratio of -22.67, a PEG ratio of 0.81 and a beta of 0.56. Supernus Pharmaceuticals, Inc. has a 1 year low of $42.45 and a 1 year high of $59.68.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its earnings results on Monday, August 3rd. The specialty pharmaceutical company reported ($1.01) EPS for the quarter, missing the consensus estimate of $0.42 by ($1.43). The company had revenue of $219.06 million for the quarter, compared to analyst estimates of $205.31 million. Supernus Pharmaceuticals had a negative net margin of 13.23% and a positive return on equity of 11.13%. Supernus Pharmaceuticals’s revenue for the quarter was up 32.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.40 earnings per share. As a group, research analysts forecast that Supernus Pharmaceuticals, Inc. will post 1.97 earnings per share for the current fiscal year.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.